LDN 072
Alternative Names: LDN-072Latest Information Update: 02 Jan 2024
Price :
$50 *
At a glance
- Originator Ladon Therapeutics
- Class Peptides; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hepatic fibrosis; Inflammatory bowel diseases; Pancreatitis
Most Recent Events
- 02 Jan 2024 Preclinical trials in Hepatic fibrosis in Hungary (Parenteral) before January 2024 (Ladon Therapeutics Pipeline, January 2024)
- 02 Jan 2024 Preclinical trials in Inflammatory bowel diseases in Hungary (Parenteral) before January 2024 (Ladon Therapeutics Pipeline, January 2024)
- 02 Jan 2024 Preclinical trials in Pancreatitis in Hungary (Parenteral) before January 2024 (Ladon Therapeutics Pipeline, January 2024)